Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent - PubMed (original) (raw)

Clinical Trial

. 2003 Jun 16;88(12):1844-50.

doi: 10.1038/sj.bjc.6600992.

P I Thompson, B C Baguley, B D Evans, V J Harvey, D J Porter, M R McCrystal, M Small, K Bellenger, L Gumbrell, G W Halbert, P Kestell; Phase I/II Trials Committee of Cancer Research UK

Affiliations

Clinical Trial

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

M B Jameson et al. Br J Cancer. 2003.

Abstract

The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects and cytokine induction. This clinical phase I trial was conducted to examine its toxicity, maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PD). A secondary objective was to assess its antitumour efficacy. DMXAA was administered every 3 weeks as a 20-min i.v. infusion. Dose escalation initially followed a modified Fibonacci schema but was also guided by PK and toxicity. A total of 63 patients received 161 courses of DMXAA over 19 dose levels ranging from 6 to 4900 mg m(-2). DMXAA was well tolerated at lower doses and no drug-related myelosuppression was seen. Rapidly reversible dose-limiting toxicities were observed at 4900 mg m(-2), including confusion, tremor, slurred speech, visual disturbance, anxiety, urinary incontinence and possible left ventricular failure. Transient prolongation of the corrected cardiac QT interval was seen in 13 patients evaluated at doses of 2000 mg m(-2) and above. A patient with metastatic cervical carcinoma achieved an unconfirmed partial response at 1100 mg m(-2), progressing after eight courses. The results of PK and PD studies are reported separately. DMXAA has antitumour activity at well-tolerated doses.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Structure of DMXAA.

Figure 2

Figure 2

Change in corrected QT interval after DMXAA administration at 3700 mg m−2.

Figure 3

Figure 3

Tumour response in a patient with metastatic squamous carcinoma of cervix treated with DMXAA 1100 mg m−2. Tumour size was calculated as the sum of the products of bidimensional measurements of three clinically measurable metastatic neck nodes.

Similar articles

Cited by

References

    1. Algire GH, Legallais FY, Park HD (1947) Vascular reactions of normal and malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marcescens (Bacillus prodigiosus) culture filtrates. J Natl Cancer Inst 8: 53–62
    1. Anderson H, Jap J, Price P (2000) Measurement of tumour and normal tissue (NT) perfusion by positron emission tomography (PET) in the evaluation of antivascular therapy: results in the phase I study of combretastatin A4 phosphate (CA4P). Proc Annu Meet Am Soc Clin Oncol 19: 179
    1. Aytemir K, Maarouf N, Gallagher MM, Yap YG, Waktare JE, Malik M (1999) Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol 22: 1397–1401 - PubMed
    1. Baguley BC, Zhuang L, Kestell P (1997) Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine–relation to vascular effects. Oncol Res 9: 55–60 - PubMed
    1. Bibby MC (1991) Flavone acetic acid–an interesting novel therapeutic agent or just another disappointment. Br J Cancer 63: 3–5 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources